| Name | Tirbanibulin Mesylate |
| Description | Tirbanibulin Mesylate (KX01 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src (GI50: 9-60 nM in cancer cell lines). |
| In vitro | Tirbanibulin Mesylate is found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. Tirbanibulin Mesylate displays steep dose-response curves against Huh7 (GI50=9 nM), PLC/PRF/5 (GI50=13 nM), Hep3B (GI50=26 nM), and HepG2 (GI50=60 nM), four hepatic cell cancer (HCC) cell lines [1]. Tirbanibulin Mesylate is evaluated in engineered Src drove cell growth assays inNIH3T3/c-Src527F and SYF/c-Src527F cells and exhibits GI50 with 23 nM and 39 nM, respectively [2]. |
| In vivo | In pre-clinical animal models of cancer, Tirbanibulin Mesylate (p.o.) is shown to inhibit primary tumor growth and to suppress metastasis [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 99 mg/mL (187.63 mM), Sonication is recommended.
|
| Keywords | KX01 | KX-01 Mesylate | KX2-391 | Src | KX 01 Mesylate | Inhibitor | inhibit | KX-01 | Tirbanibulin | KX 01 | Microtubule/Tubulin | Tirbanibulin Mesylate |
| Inhibitors Related | Flubendazole | Nintedanib | Mebendazole | N-Phenylbenzylamine | 4-Isopropoxybenzoic acid | Oxfendazole | Ibrutinib | Thiabendazole | Methylene Blue | Methylene Blue trihydrate | Paclitaxel | 4'-Demethylepipodophyllotoxin |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Microtubule-Targeted Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
